Outcome Research of a European Registry Platform on Real-world Treatment Data of Patients with Advanced NMSC

Launched by EUMELAREG GGMBH · Feb 14, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how patients with advanced non-melanoma skin cancer (NMSC), particularly Basal Cell Carcinoma (BCC) and Cutaneous Squamous Cell Carcinoma (cSCC), are treated in real-life situations across Europe. Researchers want to gather information about the characteristics of these cancers, the treatment approaches used, and the results of those treatments, helping to understand how different regions manage these conditions.

To participate in this study, you need to be at least 18 years old and have a record in the European NMSC registry that meets specific quality standards. You might be eligible if you have had surgery for high-risk cSCC and are only receiving follow-up treatments, or if you have advanced skin cancers that cannot be treated with surgery or radiation. If you join this study, you will be contributing to important research that can help improve treatment strategies for others facing similar health challenges. Your experiences and outcomes will be valuable in shaping future care for patients with advanced NMSC.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients aged ≥18 years at index date
• • 2. Patients documented in the European NMSC-registry fulfilling EMR quality standard
• • 3. Patients with resected HR-cSCC (Cohort 1) receiving only postoperative radiotherapy or watchful waiting OR Patients with advanced cSCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 2) OR Patients with advanced BCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 3)
• Exclusion Criteria:
• • 1. Patients receiving treatment within a clinical trial.